Phase 3
Completed N=366
An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
Source: ClinicalTrials.gov NCT03290781 ↗Enrolled (actual)
366
Serious AEs
7.9%
Results posted
Jan 2022
Primary outcomePrimary: Number of Participants With Remission Based on Composite Score at Week 52 — 6; 38; 11; 33 Participants — p=<0.001
◆ Published Evidence
Emerging
17citations · ~9 / year
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
Summary
The purpose of this study is to evaluate the efficacy of ontamalimab as maintenance therapy treatment of remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).
Linked Publications
-
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Remission Based on Composite Score at Week 52 |
6; 38; 11; 33 | <0.001 sig |
| SECONDARY Number of Participants With Endoscopic Remission at Week 52 |
7; 40; 13; 40 | <0.001 sig |
| SECONDARY Number of Participants With Clinical Remission at Week 52 |
13; 48; 19; 42 | <0.001 sig |
| SECONDARY Number of Participants With Sustained Remission at Week 52 |
4; 23; 7; 22 | <0.001 sig |
| SECONDARY Number of Participants With Clinical Response Based on Composite Score at Week 52 |
15; 49; 20; 47 | <0.001 sig |
| SECONDARY Number of Participants With Mucosal Healing Based on Endoscopic and Histologic Assessment at Week 52 |
6; 37; 11; 29 | <0.001 sig |
| SECONDARY Number of Participants With Glucocorticoid-free Clinical Remission at Week 52 |
1; 12; 3; 12 | <0.001 sig |
| SECONDARY Number of Participants With Glucocorticoid-free Remission at Week 52 |
0; 8; 2; 10 | <0.001 sig |
| SECONDARY Number of Participants With Remission Based on Total Mayo Score at Week 52 |
5; 38; 10; 33 | — |
| SECONDARY Number of Participants With Clinical Remission Based on Both Rectal Bleeding and Stool Frequency Sub-scores of 0 |
28; 25; 25; 24; 22; 25 | — |
| SECONDARY Number of Participants With Sustained Endoscopic Remission at Week 52 |
4; 27; 8; 29 | — |
| SECONDARY Number of Participants With Treatment Emergent Adverse Events (TEAEs) |
46; 41; 54; 51; 8; 11 | — |
| SECONDARY Number of Participants Who Developed Positive Antidrug Antibodies to Ontamalimab |
7; 6; 8; 4; 2; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Participants and/or their parent or legally authorized representative must have an understanding, ability, and willingness to fully comply with study procedures and restrictions.
- Participants must be able to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent and/or assent, as applicable, to participate in the study.
- Participants must have completed the 12-week induction treatment period (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]).
- Participants must have achieved clinical response in induction study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]). Clinical response is defined as:
i) A decrease from the induction study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) baseline in the composite score of patient reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30 percent (%), with an accompanying decrease in the sub score for rectal bleeding greater than or equal to (>=) 1 point or a sub score for rectal bleeding less than or equal to (<=) 1 OR ii) A decrease from the induction study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) baseline in total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding sub score of at least 1 point or an absolute rectal bleeding sub score of 0 or 1.
For eligibility assessment, clinical response will be determined based on the centrally read endoscopy performed during screening and at Week 12 of induction study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]).
- Participants receiving any treatment(s) for ulcerative colitis (UC) are eligible provided they have been, and are anticipated to be, on a stable dose for the designated period of time.
Exclusion Criteria
- Participants who had major protocol deviation(s) (as determined by the sponsor) in induction study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]).
- Participants who permanently discontinued investigational product because of an adverse event (AE), regardless of relatedness to investigational product, in induction study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]).
- Participants who are likely to require surgery for UC during the study period.
- Participants are females who became pregnant during induction study (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]), females who are planning to become pregnant during the study period, or males or females of childbearing potential not agreeing to continue using appropriate contraception methods (that is [i.e,] highly effective methods for female and medically appropriate methods for male study participants) through the conclusion of study participation.
- Participants who do not agree to postpone donation of any organ or tissue, including male participants who are planning to bank or donate sperm and female participants who are planning to harvest or donate eggs, for the duration of the study and through 16 weeks after last dose of investigational product.
- Participants who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
- Participants who have a newly diagnosed malignancy or recurrence of malignancy (other than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
- Participants who have developed any major illness/condition or evidence of an unstable clinical condition (example [eg], renal, hepatic, hematologic, gastrointestinal (except disease under study), endocrine, cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study.
- Participants with any other severe acute
Data sourced from ClinicalTrials.gov (NCT03290781) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.